Hutchmed GSK Deal: $110 Million Upfront Plus Up to $1.185 Billion Milestones

Hutchmed will receive a $110 million upfront payment from GSK and is eligible for up to $1.185 billion in development, regulatory and commercialization milestone payments, plus tiered royalties on net sales. The molecule involved was still in preclinical stage at the time; the Phase Ia portion of the global Phase I trial only began in September. The materials state the upfront payment will arrive 48 days later.